Background-Thrombolytic treatment
Patients-608 consecutive patients (447 men and 161 women) with confirmed myocardial infarction who were admitted to the coronary care unit of a district general hospital between January 1989 and December 1991 . Clinical details, including the development of left ventricular failure and in hospital adverse events, were recorded prospectively. Follow up for out of hospital adverse events was carried out by review of the case notes, postal questionnaire, and where necessary, by telephone contact with the patient and his general practitioner. Results-The risk (95% confidence interval) of major adverse events in the first 10 days was 32*3% (26-3 to 39.4%/6) in patients with heart failure and 7-3% (5.1 to 9-2%) in those without. Smoothed estimates of the event rate in patients without heart failure decreased from 5-9 events/1000 personslday on day 6 to 3-4 events/1000 personslday on day 10 and 0'9 events/ 1000 persons/day on day 21. The corresponding cumulative risk estimates suggest that about 11 in every 1000 patients suffer a major, but often unpreventable, adverse event on day 6 or 7 after admission, and 23 in every 1000 do so between days 6 and 10.
Conclusions-The point at which the risk to the individual becomes acceptably low is a matter of judgement, but the risk of a major adverse event declines rapidly after a heart attack, and particularly for patients without heart failure discharge within a few days may be appropriate. Prolonging Thrombolytic treatment reduces hospital mortality,"3 14 but is associated with recurrent thrombotic events, and it is unclear how this affects the safety of early discharge.'5 16 The risks of major adverse events in general hospital patients has not been systematically quantified since the introduction of thrombolysis, yet lengths of stay continue to decrease. We have previously reported the follow up of a consecutive series of patients with confirmed myocardial infarction from a district general hospital in east London'7 and we have used data from this study to examine the risk of major adverse events in the early postinfarction period.
Patients and methods
The methods are described in our previous report but are summarized here. ' 
Results
Some 196 patients (32%) developed clinical evidence of heart failure (left ventricular failure with or without cardiogenic shock). These patients were older than those without heart failure, a higher proportion were women, and more were diabetic or had a history of previous infarction; a smaller proportion had received thrombolysis (table 1) . Seventy five patients eventually underwent revascularisation, but only 18 did so in the first 10 days: two (1%) of those with heart failure and 16 (4%) of those without. Table 2 gives multivariate predictors of adverse events within 10 days. Heart failure was the most important, with an odds ratio of 3-47. The probability of developing a major event by 10 days was 32-3% (95% confidence interval (CI) 26-3 to 39 4%) in patients with heart failure and 7-3% (95% CI 5-1 to 9 2%) in those without (fig 1) . Older age, female sex, the presence of bundle branch block, and ventricular tachycardia were associated with increased risk, but primary ventricular fibrillation was not. Thrombolysis and aspirin use were associated with lower risk. ._ 
RATES OF ADVERSE EVENTS
The rate of major adverse events was analysed separately for patients with and without heart failure because of the prognostic importance of ventricular function. Figure 2 shows the change over time for the two groups. Patients with heart failure had a high rate in the first few days which rapidly diminished. The regression fit suggests that the incidence fell from 21-3 events/1000 persons on day 6 to 9.0 events/1000 persons on day 10 and 3-6 events/1000 persons on day 21. Rates in those without heart failure were substantially lower with corresponding figures at 6, 10, and 21 days of 5 9, 3 4, and 0'9 events/1000 persons/day. The cumulative risk in this group was 1I1% between days 6 and 7 and 2-3% between days 6 and 10. A total of six adverse events were actually observed on days 6 and 7 in patients without heart failure, which represents an event rate for these two days of 7 65 (95% CI 2.81 to 16-7) events/1000 persons/day. This is slightly greater than the smoothed estimate from the regression fit. Over the five day period of days 6-10 13 patients without heart failure developed a major event; the corresponding rate was 6-72 (95% CI 3-58 to 11 49) events/1000 persons/day-again higher than the smoothed estimate. Table 3 gives the characteristics of those without heart failure who developed a major adverse event between days 6 and 10. There were four in hospital deaths, five non-fatal reinfarctions, and three readmissions with unstable angina. The single episode of secondary ventricular fibrillation occurred immediately after coronary angiography. This table indicates that of 412 patients without heart failure, only five developed a major adverse event shortly after hospital discharge.
Review of the case notes suggested that of the 13 patients who developed a major adverse event between days 6 and 10, only five would probably have been fit for discharge after five days because of various medical problems. One of these died in hospital on day 6 , one developed unstable angina on day 10, and three had reinfarction (one on day 8 and two on day 10).
COSTS AND BENEFITS
It was not possible to quantify all costs and benefits of early discharge, but estimates were obtained of the potential saving on hospital care, and the expected additional number of adverse events which would occur outside hospital. The latter was computed from the smoothed estimates of risk, and the breakdown of different types of event-that is, death, reinfarction, secondary ventricular fibrillation, and unstable angina, was based on the proportions observed between 6 and 10 days. The calculations assume that all patients would be fit for discharge after five days and that the same complications would occur whether the patients were in hospital or at home.
For 1000 patients without heart failure discharge after five days rather than seven would increase the number of out of hospital events by about 10-9: 3.4 deaths, 0-8 episodes of secondary ventricular fibrillation, 2-5 recurrent heart attacks, and 4-2 episodes of unstable angina. The cost of a bed on a general medical ward was estimated to be £140 per day, excluding specific investigation and treatment. Thus, for 1000 patients the approximate saving would be 2000 bed days at a nominal cost of £280 000, although it may not be possible to redirect these resources to other uses.
Discharge after five days rather than 10 would save 5000 bed days at a cost of £700 000 but be accompanied by the following out of nl _, m z= Table 3 Characteristics ofpatients without heartfailure who suffered a major adverse event between days 6 and 10 after admission Early discharge puts at risk a small additional number of patients and reduces the time available for in hospital rehabilitation and investigation (such as pre-discharge exercise electrocardiography), but may also have physical and psychological benefits. The resource implications may be substantial: the additional cost of hospital care amounts to around £25 000 for each major complication on days 6 and 7 after admission, and many of these complications are not preventable. It is worth noting, for example, that in our study all deaths between six and 10 days occurred in hospital. Thus, early discharge could potentially save considerable resources which might be more effectively used to treat coronary disease in other ways.
The timing of discharge for patients with heart failure is often determined by clinical factors, but clinicians should be aware that for many patients without heart failure the risks of an adverse event are small and it seems reasonable to consider their discharge at five days or sometimes even earlier. Of course, each case must be decided individually on the basis of clinical assessment and any general policy flexibly applied. It may be appropriate to allow the early discharge of young, fit patients with good family support, but clinical judgement is always important and it is often social circumstances which dictate the timing of discharge rather than purely clinical considerations.
